Table 1 Patient demographic and clinical characteristics
|  | Prior to matching (n = 91) | Matched (n = 62) | ||||
|---|---|---|---|---|---|---|
|  | Not reversed (n = 40) | Reversed (n = 51) | P | Not Reversed (N = 31) | Reversed (N = 31) | P |
Age* | 81 (8) | 82 (8) |  < 0.01 | 81 (8) | 81 (8) | 0.96 |
Sex, % female (n) | 30% (12) | 47% (24) | 0.10 | 65% (20) | 81% (25) | 0.33 |
Race, % white (n) | 98% (39) | 100% (51) | 0.44 | 97% (30) | 100% (31) |  > 0.99 |
Prior fracture | 3% (1) | 16% (8) | 0.07 | 3% (1) | 13% (4) | 0.25 |
Walking independent preinjury, % (n) | 63% (25) | 55% (28) | 0.39 | 58% (18) | 45% (14) | 0.31 |
Comorbidities | ||||||
 CHF | 10% (4) | 29% (15) | 0.02 | 13% (4) | 13% (4) |  > 0.99 |
 Dementia | 5% (2) | 22% (11) | 0.03 | 6% (2) | 6% (2) |  > 0.99 |
 COPD | 3% (1) | 20% (10) | 0.02 | 3% (1) | 13% (4) | 0.38 |
 Diabetes | 13% (5) | 27% (14) | 0.08 | 19% (6) | 23% (7) | 0.73 |
 CVA | 3% (1) | 14% (7) | 0.07 | 3% (1) | 13% (4) | 0.38 |
 Hypertension | 63% (25) | 69% (35) | 0.66 | 68% (21) | 65% (20) |  > 0.99 |
 CAD | 3% (1) | 0% (0) | 0.44 | 3% (1) | 0% (0) |  > 0.99 |
 Smoker | 5% (2) | 6% (3) |  > 0.99 | 6% (2) | 6% (2) |  > 0.99 |
 Comorbidity count | 2 (1) | 3 (2) |  < 0.01 | 2 (1) | 2 (1) | 0.62 |
Pre-injury medications | ||||||
 Beta blocker | 35% (14) | 59% (30) | 0.03 | 32% (10) | 61% (19) | 0.03 |
 Analgesic | 28% (11) | 24% (12) | 0.81 | 19% (6) | 23% (7) |  > 0.99 |
 Narcotic | 23% (9) | 27% (14) | 0.63 | 26% (8) | 26% (8) |  > 0.99 |
 Antibiotic | 5% (2) | 12% (6) | 0.46 | 3% (1) | 6% (2) |  > 0.99 |
 Steroid | 18% (7) | 24% (12) | 0.48 | 19% (6) | 26% (8) | 0.75 |
 Calcium | 13% (5) | 8% (4) | 0.50 | 10% (3) | 6% (2) |  > 0.99 |
Pre-injury DOAC medication | ||||||
 Rivaroxaban | 65% (26) | 47% (24) | 0.09 | 61% (19) | 48% (15) | 0.48 |
 Apixaban | 33% (13) | 39% (20) | 0.66 | 35% (11) | 42% (13) | 0.79 |
 Dabigatran | 3% (1) | 12% (6) | 0.13 | 3% (1) | 6% (2) |  > 0.99 |
 Edoxaban | 0% (0) | 2% (1) |  > 0.99 | 0% (0) | 3% (1) |  > 0.99 |
DOAC indication | ||||||
 Atrial fibrillation | 68% (27) | 78% (40) | 0.34 | 68% (21) | 81% (25) | 0.42 |
 CAD | 13% (5) | 10% (5) | 0.74 | 13% (4) | 6% (2) | 0.69 |
 DVT or PE | 15% (6) | 12% (6) | 0.76 | 13% (4) | 13% (4) |  > 0.99 |
 Stroke or CVA | 8% (3) | 8% (4) |  > 0.99 | 6% (2) | 6% (2) |  > 0.99 |
Fracture type | ||||||
 Femoral neck | 63% (25) | 57% (29) | 0.57 | 58% (18) | 58% (18) |  > 0.99 |
 Intertrochanteric | 38% (15) | 39% (20) | 0.87 | 42% (13) | 39% (12) |  > 0.99 |
 Subtrochanteric | 0% (0) | 4% (2) | 0.50 | 0% (0) | 3% (1) |  > 0.99 |
Surgical procedurea | ||||||
 Intramedullary fixation | 45% (18) | 43% (22) |  > 0.99 | 55% (17) | 35% (11) | 0.21 |
 Hemiarthroplasty | 25% (10) | 31% (16) | 0.64 | 26% (8) | 32% (10) | 0.77 |
 Internal fixation | 18% (7) | 25% (13) | 0.45 | 13% (4) | 29% (9) | 0.18 |
 Bipolar hemiarthroplasty | 20% (8) | 8% (4) | 0.09 | 77% (24) | 10% (3) | 0.34 |
 Total hip arthroplasty | 20% (8) | 4% (2) | 0.02 | 13% (4) | 6% (2) | 0.63 |
 Individual screw placement | 3% (1) | 4% (2) |  > 0.99 | 0% (0) | 3% (1) |  > 0.99 |
Pre-operative hemoglobina | 13.4 (2.3) | 12.0 (3.2) |  < 0.01 | 13.5 (2.1) | 11.5 (2.8) | 0.78 |
Abnormal CrCl, % (n) | 88% (35) | 100% (51) | 0.01 | 87% (27) | 100% (31) |  > 0.99 |
Arrival to surgery, hoursa | 18 (11) | 43 (21) |  < 0.01 | 18 (12) | 43 (22) |  < 0.01 |
Last dose to surgery, hoursb | 21 (16, 23) | 55 (37, 71) |  < 0.01 | 20 (15, 23) | 55 (37, 71) |  < 0.01 |